ArticleBritish journal of cancer2026
The association between hospital frailty risk score and adverse inpatient outcomes in older adults with colorectal cancer.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImpact of frailty on prognosis in patients with metastatic and non-metastatic colorectal cancer (CRC) was studied.
methodsPatients aged ≥60 years with CRC were identified in Nationwide Inpatient Sample database and analyzed retrospectively. Frailty was defined when Hospital Frailty Risk Score ≥5. Patients were grouped and matched by metastatic status. Logistic and linear regression were used to assess association between frailty and in-hospital outcomes.
resultsAfter matching, 99,017 metastatic and 418,435 non-metastatic CRC were included. Frailty was significantly associated with increased in-hospital mortality (metastatic: OR = 1.10, 95% CI 1.05-1.17; non-metastatic: aOR = 1.05, 95% CI 1.00-1.10), prolonged length of stay (metastatic: OR = 1.30, 95% CI 1.26-1.34; non-metastatic: aOR = 1.37, 95% CI 1.34-1.39), and discharge to long-term care (metastatic: OR = 1.67, 95% CI 1.62-1.73; non-metastatic: aOR = 2.10, 95% CI 2.07-2.14). Frailty was also associated with higher total hospital costs, with additional $3,750 (95% CI $2940-$4560) in metastatic CRC and $1920 (95% CI $1480-$2360) in non-metastatic CRC.
conclusionsFrailty is an independent predictor of adverse outcomes among older patients with CRC, regardless of metastatic status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.